Latest Breaking News On - Program update for dengue - Page 1 : comparemela.com

10.05.2022 - New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical .

United statesJean pierre sommadossiJonae barnesFounder of atea pharmaceuticalsBemnifosbuvir clinical developmentNature communicationsDrug administrationProgram update for dengueSee the companyDevelopment expensesAtea pharmaceuticalsCombination programCorporate communicationsAtea pharmaceuticals incRisk assessment specialty selection executive committeeExecutive officer